Great Point Partners as of March 31, 2018
Portfolio Holdings for Great Point Partners
Great Point Partners holds 32 positions in its portfolio as reported in the March 2018 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Iovance Biotherapeutics (IOVA) | 8.3 | $56M | 3.3M | 16.90 | |
Arena Pharmaceuticals | 7.8 | $52M | 1.3M | 39.50 | |
Ptc Therapeutics I (PTCT) | 7.0 | $47M | 1.7M | 27.06 | |
Kura Oncology (KURA) | 6.6 | $45M | 2.4M | 18.75 | |
Zogenix | 5.8 | $39M | 978k | 40.05 | |
Spark Therapeutics | 5.4 | $37M | 550k | 66.59 | |
Global Blood Therapeutics In | 5.3 | $36M | 742k | 48.30 | |
BioCryst Pharmaceuticals (BCRX) | 5.3 | $36M | 7.5M | 4.77 | |
Puma Biotechnology (PBYI) | 5.0 | $34M | 500k | 68.05 | |
Neurocrine Biosciences (NBIX) | 4.9 | $33M | 400k | 82.93 | |
Rigel Pharmaceuticals (RIGL) | 4.5 | $30M | 8.6M | 3.54 | |
Aimmune Therapeutics | 4.3 | $29M | 901k | 31.83 | |
Foamix Pharmaceuticals | 3.6 | $25M | 4.8M | 5.13 | |
Exelixis (EXEL) | 3.0 | $20M | 900k | 22.15 | |
Prothena (PRTA) | 2.7 | $18M | 500k | 36.71 | |
Acceleron Pharma | 2.7 | $18M | 462k | 39.10 | |
Novocure Ltd ord (NVCR) | 2.4 | $16M | 754k | 21.80 | |
Five Prime Therapeutics | 2.2 | $15M | 868k | 17.18 | |
Achillion Pharmaceuticals | 2.0 | $14M | 3.7M | 3.71 | |
Endocyte | 2.0 | $14M | 1.5M | 9.09 | |
Corsicanto Ii Designated Act note | 1.6 | $11M | 10M | 1.10 | |
Savara (SVRA) | 1.2 | $7.9M | 862k | 9.20 | |
Cti Biopharma | 1.0 | $6.6M | 1.7M | 3.90 | |
Amarin Corporation (AMRN) | 1.0 | $6.5M | 2.2M | 3.01 | |
Catalyst Pharmaceutical Partners (CPRX) | 1.0 | $6.4M | 2.7M | 2.39 | |
Sierra Oncology | 1.0 | $6.4M | 3.1M | 2.07 | |
Vanda Pharmaceuticals (VNDA) | 0.8 | $5.2M | 310k | 16.85 | |
Acorda Therapeutics | 0.8 | $5.2M | 219k | 23.65 | |
Menlo Therapeutics | 0.3 | $2.0M | 52k | 37.57 | |
Newlink Genetics Corporation | 0.2 | $1.7M | 234k | 7.25 | |
Antares Pharma | 0.2 | $1.1M | 500k | 2.20 | |
Streamline Health Solutions (STRM) | 0.0 | $239k | 130k | 1.84 |